Immune cell 'boost' aims to clear leukemia before transplant
NCT ID NCT07591649
First seen May 19, 2026 · Last updated May 24, 2026 · Updated 2 times
Summary
This study tests a new immune cell treatment called AdaptNK for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses specially grown natural killer cells from a donor to attack the leukemia, followed by a stem cell transplant. The goal is to see if this approach is safe and can help achieve remission before the transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mark Juckett, MD
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.